Back to search results
NCT07636200

The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer

Recruiting
NAAges 18+InterventionalSupportive care
University of Colorado, Boulder
~250 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Written Exposure-Based Coping Intervention (EASE)Usual Care Control Condition

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Fear of Progression Questionnaire, Short Form (with cancer as the disease)
Measured over Assessed four times with parallel timing in the control group: prior to the intervention (Pre), following session 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 3-month follow-up (FU).
+1 more outcome measured

Conditions

Advanced Solid Tumor Cancer
Stage IV Cancer (Solid Tumors Only)
Glioblastoma
Stage III Ovarian Cancer
Small Cell Lung Cancer Extensive Stage

Explore related trials

GlioblastomaLung Small Cell CarcinomaMalignant Ovarian NeoplasmSolid Neoplasm

NCT07636200

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Colorado Anschutz Medical Campus

    Aurora, Coloradostudy coordinator listed

    Recruiting

  • University of Colorado Boulder

    Boulder, Coloradostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Joanna Arch, PhD
[email protected]
720-897-1850
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults, age 18 or older
Have been diagnosed with either (a) Stage IV metastatic cancer of any solid tumor type, (b) Stage III ovarian cancer that has recurred, (c) 'extensive stage' small cell lung cancer, or (d) glioblastomas of any staging
Are capable at time of consent of understanding and voluntarily consenting themselves to the study, attending intervention sessions, and writing for 30 minutes, confirmed by an Eastern Cooperative Group Performance Status Scale of ≤2
Report elevated FoP and cancer-related trauma symptoms on the screening measures: FoP-Q 12-item short version: mean score of 2.5 (or total score of 30), IES-R: mean of 1.5 (or total score of 33)
Are fluent in English or Spanish and can read English proficiently (for the surveys, which are in English)

Exclusion

Patients who have a history of chronic untreated trauma unrelated to their cancer, psychiatric hospitalization or suicide attempt(s) in the past 2 years, or current high suicide risk, as identified in the screening.
EMR-noted cognitive impairment (such as dementia) is an exclusion due to potential impairments in neural learning mechanisms that may affect the efficacy of exposure therapy.

What this trial measures

  • Fear of Progression Questionnaire, Short Form (with cancer as the disease)Assessed four times with parallel timing in the control group: prior to the intervention (Pre), following session 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 3-month follow-up (FU).

    Assesses fear of cancer progression. Higher scores = higher fear of progression.

  • Impact of Events Scale-Revised (with cancer as the event)Assessed four times with parallel timing in the control group: prior to the intervention (Pre), following session 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 3-month follow-up (FU).

    Cancer-related trauma symptoms. Higher scores = higher symptom levels.